CIP
CPRX

Cornerstone Investment Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Cornerstone Investment Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22,925
Closed -$190K – 208
2022
Q1 		$190K Buy
+22,925
New +$162K 0.01% 210
2021
Q1 		– Sell
-46,615
Closed -$156K – 276
2020
Q4 		$156K Buy
+46,615
New +$157K 0.01% 195

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cornerstone Investment Partners's CPRX Position: Q2 2022 in Review

Cornerstone Investment Partners sold out of Catalyst Pharmaceutical (CPRX) in Q2 2022, closing a stake of 22,925 shares — an estimated $190K sold.

Cornerstone Investment Partners first reported a position in CPRX in Q4 2020 and held it in 2 quarters. The position peaked at $190K in Q1 2022. 189 funds tracked by Wall St. Rank hold CPRX as of Q2 2022.

  • Cornerstone Investment Partners reported no remaining Catalyst Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Cornerstone Investment Partners sold 22,925 Catalyst Pharmaceutical shares in Q2 2022, an estimated $190K.
  • Cornerstone Investment Partners first reported a position in Catalyst Pharmaceutical in Q4 2020 and held it in 2 quarters.
  • Cornerstone Investment Partners's Catalyst Pharmaceutical position peaked at $190K in Q1 2022.
  • 189 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2022.

Based on Cornerstone Investment Partners's 13F filing for Q2 2022, filed 29 Jul 2022.